NEVVI Medicare utilization intelligence
or

← back

Provider profile

SILVER, JOEL M.D.

Hematology-Oncology · NPI 1013976299 · HARTFORD, CT

1
Groups
20
Codes · 2024
15,484
Disclosed services

SILVER, JOEL is a Hematology-Oncology in HARTFORD, CT, a member of 1 medical group, who billed 20 distinct codes to Medicare Part B in 2024.

Groups: REGIONAL CANCER CARE ASSOCIATES LLC (HACKENSACK, NJ)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

15,484
disclosed services
20
codes billed to Medicare Part B
Prior year · CY2023 22,998 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0897 Injection, denosumab, 1 mg
Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
J1437 Injection, ferric derisomaltose, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96372 Injection of drug or substance under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96413 Administration of chemotherapy into vein, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
96375 Injection of additional new drug or substance into vein
96415 Administration of chemotherapy into vein, each additional hour
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
38222 Biopsy and aspiration of bone marrow sample for diagnosis

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.